During the past decade, Krishna Institute of Medical Sciences conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 7 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Krishna Institute of Medical Sciences" #1 sponsor was "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 3 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Actelion" with 1 trials sponsored, "Bayer" with 1 trials sponsored and "CSL Behring" with 1 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Krishna Institute of Medical Sciences" #1 collaborator was "Asian Clinical Trials" with 1 trials as a collaborator, "Cadila Pharnmaceuticals" with 1 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Glenmark Pharmaceuticals S.A." with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Krishna Institute of Medical Sciences" are "Rheumatoid Arthritis" (4 trials), "Fibromyalgia" (2 trials), "Acute Coronary Syndrome" (1 trials), "Arthritis, Rheumatoid" (1 trials) and "Caloric Deficit" (1 trials). Many other conditions were trialed in "Krishna Institute of Medical Sciences" in a lesser frequency.

Most popular intervention types in "Krishna Institute of Medical Sciences" are "Drug" (15 trials), "Biological" (3 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "placebo" (3 trials), "ALD518" (1 trials), "Abluminus DES+ Sirolimus Eluting Stent System (SES)" (1 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Krishna Institute of Medical Sciences" are 20 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Krishna Institute of Medical Sciences". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in Krishna Institute of Medical Sciences, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Krishna Institute of Medical Sciences, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 3 trials that are defined as “Not Applicable".